Yaound, Cameroon, 15th November 2005 Clinical results demonstrating the potential benefits of treating Plasmodium falciparum malaria with a new artemisinin-based combination therapy (ACT), chlorproguanil hydrochloride-dapsone-artesunate (CDA)1, were announced today at the 4th Multilateral Initiative on Malaria (MIM) Pan-African Conference in Cameroon. CDA is being developed to meet the urgent need for new malaria treatments for Africa where drug resistance is contributing to an escalating health crisis. Dr. Arata Kochi, Director of the WHO Roll Back Malaria (RBM) Department stated, "The effort to develop CDA responds to RBM's call for fixed-dose artemisinin containing combinations."
The phase II trial of CDA, involving adults and children with P. falciparum malaria, was designed to determine the optimum dose of artesunate in combination with LapdapTM (chlorproguanil/dapsone). Treatment with CDA, at three doses of artesunate (1, 2 and 4mg/kg) in adults and at two doses (2 and 4mg/kg) in children, led to faster time to reduce parasite levels in the blood by 90 percent when compared to treatment with Lapdap alone.1 Reductions in parasite viability and potential parasite reproductive ability in patients were also greater in those treated with CDA than Lapdap alone. All treatment doses of CDA were generally well tolerated, and the nature and incidence of adverse events were similar across treatment groups.1
"These results suggest that CDA could become a major weapon in the fight against drug-resistant malaria. Moving into phase III trials marks a key step in the development of this promising antimalarial," commented Dr. Chris Hentschel, CEO of MMV.
Phase III trials for CDA are planned across sub-Saharan Africa and will further study the safety and efficacy of treating P. falciparum malaria with CDA. One study will compare CDA against the only fixed-dose ACT currently available for the treatment of P. falciparum, artemether/lumefantrine, over a Page: 1 2 Related biology news :1
. Cost-effectiveness study of three antimalarial drug combinations in Tanzania2
. Research milestone brings goal closer of cheap antimalarial drug for developing world3
. $43 million from Gates Foundation to produce inexpensive antimalarial drug for Third World4
. Cetuximab and irinotecan combination increases survival in metastatic colorectal cancer5
. New study suggests promising drug combinations for sleeping sickness6
. Recombination protein dynamics observed with single monomer resolution7
. AVELOX as effective as multi-dose combination therapy for intra-abdominal infections8
. New combination treatment induces regression of prostate cancer9
. Avelox as effective as Levofloxacin combination therapy for severe community-acquired pneumonia10
. New observational study suggests use of combination vaccines may improve immunization coverage rates in infants11
. Pesticide combinations imperil frogs, probably contribute to amphibian decline